PARIS--(BUSINESS WIRE)--Regulatory news: BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented preclinical results on its new biotherapy, AMEP™ for advanced and metastatic melanoma at the ESGCT (European Society of Gene and Cell Therapy) in Hannover (November 21 to 25, 2009).
